Background & objectives: Several components of metabolic syndrome (MetS) facilitate its diagnosis, including abdominal obesity, hyperlipidemia, high blood pressure, and insulin resistance. The production of interleukin–6 (IL–6) and adipokines seem to be associated with MetS components. Elevated proinflammatory cytokines show an emerging role in the patients with Metabolic syndrome. The production of interleukin–6 seems to be strong association in patients with Met–S. These components may form a target for novel treatment approaches. The main objectives of this study was to evaluate & estimate the serum levels IL–6 and adipokines with MetS and its components Methods: We studied 45 subjects, with Metabolic syndrome, diagnosed by International Diabetes Federation (IDF) criteria and 45 healthy control subjects, age below 40 years, Male subjects. We compared the circulating levels of the serum IL–6 and adipokines levels were estimated using the ELISA in Metabolic Syndrome with onset of Type 2 Diabetes with clinical settings. Results: Serum levels of IL–6 and adipokines were found to be significant difference between serum levels of IL–6 and adipokines in Metabolic Syndrome with type 2 diabetic cases than in control subjects (IL–6; 27.53 ± 2.61 vs 6.07 ± 1.76 pg/ml & 𝑃 < 0.001). Further, serum levels of adiponectin were found significant decreased and serum level of leptin were found significantly increased in cases with Metabolic Syndrome and type 2 diabetes than in control group (𝑃 < 0.001) Interpretation & conclusions: Patients with MetS had significantly greater serum IL–6 than the controls, supporting the evidence that inflammation plays an important role in the immunopathogenesis of the disease. Additionally, IL–6 and adipokines serum levels may predict MetS.